Evolving meningococcal immunization strategies

The Impact of the Meningococcal Serogroup C Conjugate Vaccine in Canada Between 2002 and 2012

(2014) M. Sadarangani et al.   CLINICAL INFECTIOUS DISEASES

A Consensus Statement

(2014) Ricardo Walter Rüttimann et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Timing of an Adolescent Booster after Single Primary Meningococcal Serogroup C Conjugate Immunization at Young Age; An Intervention Study among Dutch Teenagers

(2014) Susanne P. Stoof et al.   PLoS One

Emergencia de la cepa W135 causante de enfermedad meningocócica invasora en Chile 2012

(2014) M. Teresa Valenzuela et al.   REVISTA MEDICA DE CHILE

Safety of a quadrivalent meningococcal serogroups A, C, W and Y conjugate vaccine (MenACWY-CRM) administered with routine infant vaccinations: Results of an open-label, randomized, phase 3b controlled study in healthy infants

(2014) Arturo Abdelnour et al.   VACCINE

Meningococcal Disease: Epidemiology and Early Effects of Immunization Programs

(2014) M. A. P. Safadi et al.   Journal of the Pediatric Infectious Diseases Society

Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination

(2013) Jean-Marc Collard et al.   BMC INFECTIOUS DISEASES

Controlling serogroup B invasive meningococcal disease: the Canadian perspective

(2013) Julie A Bettinger et al.   Expert Review of Vaccines

The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative

(2013) Marco Aurélio P Sáfadi et al.   Expert Review of Vaccines

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

(2013) Natalie G Martin et al.   Expert Review of Vaccines

Effect of a serogroup A meningococcal conjugate vaccine (PsA–TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study

(2013) DM Daugla et al.   LANCET

Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

(2013) Caroline L. Trotter et al.   PLoS One

Enfermedad meningocóccica: siempre presente. Cambios en los serogrupos en el Cono Sur

(2013) Eduardo Luis López et al.   Revista Chilena de Infectologia

An overview of meningococcal disease in India: Knowledge gaps and potential solutions

(2013) T. Jacob John et al.   VACCINE

Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): Lessons from past programs and implications for the future

(2013) Johan Holst et al.   Human Vaccines & Immunotherapeutics

Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction

(2012) David A. Ishola et al.   Clinical and Vaccine Immunology

Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity

(2012) Paul A. Kristiansen, Fabien Diomandé, Absatou Ky Ba, Idrissa Sanou, Abdoul–Salam Ouédraogo, Rasmata Ouédraogo, Lassana Sangaré, Denis Kandolo, Flavien Aké, Inger Marie Saga, Thomas A. Clark, Lara Misegades, Stacey W. Martin, Jennifer Dolan Thomas, Sylvestre R. Tiendrebeogo, Musa Hassan-King, Mamoudou H. Djingarey, Nancy E. Messonnier, Marie-Pierre Préziosi, F. Marc LaForce, Dominique A. Caugant   CLINICAL INFECTIOUS DISEASES

Invasive Serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: Persistence of the ST-269 Clone Since It First Emerged in 2003

(2012) J. Zhou et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Clonal Analysis of Neisseria meningitidis Serogroup B Strains in South Africa, 2002 to 2006: Emergence of New Clone ST-4240/6688

(2012) C. Moodley et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

(2012) Ryan T Novak et al.   LANCET INFECTIOUS DISEASES

Immunogenicity of a Single Dose of Meningococcal Group C Conjugate Vaccine Given at 3 Months of Age to Healthy Infants in the United Kingdom

(2012) Helen Findlow et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Disease Burden of Invasive Meningococcal Serogroup B Disease in Canada

(2012) Julie A. Bettinger et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Changing Epidemiology of Meningococcal Disease in Quebec, Canada, 1991–2011: Potential Implications of Emergence of New Strains

(2012) Rodica Gilca et al.   PLoS One

Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial

(2012) Siddhivinayak Hirve et al.   VACCINE

Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis

(2012) Julie A. Bettinger et al.   VACCINE

Critical episodes in the understanding and control of epidemic meningococcal meningitis

(2012) Andrew W. Artenstein et al.   VACCINE

A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years

(2012) Timo Vesikari et al.   Human Vaccines & Immunotherapeutics

Development of a group A meningococcal conjugate vaccine,MenAfriVacTM

(2012) Carl Frasch et al.   Human Vaccines & Immunotherapeutics

Study of a Localized Meningococcal Meningitis Epidemic in Burkina Faso: Incidence, Carriage, and Immunity

(2011) Judith E. Mueller et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

(2011) Samba O. Sow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emergence of Epidemic Neisseria meningitidis Serogroup X Meningitis in Togo and Burkina Faso

(2011) Isabelle Delrieu et al.   PLoS One

The Global Meningococcal Initiative: Recommendations for reducing the global burden of meningococcal disease

(2011) Lee H. Harrison et al.   VACCINE

The epidemiology of meningococcal disease in India

(2010) David Sinclair et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Kinetics of Antibody Persistence following Administration of a Combination Meningococcal Serogroup C and Haemophilus influenzae Type b Conjugate Vaccine in Healthy Infants in the United Kingdom Primed with a Monovalent Meningococcal Serogroup C Vaccine

(2009) R. Borrow et al.   Clinical and Vaccine Immunology

The Impact of Childhood Meningococcal Serogroup C Conjugate Vaccine Programs in Canada

(2009) Julie A. Bettinger et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000–2006

(2009) Laura M. Kinlin et al.   VACCINE

Meningococcal C conjugate vaccine: The experience in England and Wales

(2009) Helen Campbell et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

Serogroup B meningococcal disease during Hajj: Preparing for the worst scenario

(2009) Mohamed K.M. Khalil et al.   Travel Medicine and Infectious Disease

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom

(2008) J. Southern et al.   Clinical and Vaccine Immunology

Seroprevalence of Antibodies against Serogroup C Meningococci in England in the Postvaccination Era

(2008) C. L. Trotter et al.   Clinical and Vaccine Immunology

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

(2008) Martin C. J. Maiden et al.   JOURNAL OF INFECTIOUS DISEASES